16 November 2021 07:00 GMT
Almost two thirds of vaccine doses delivered to low- and lower-middle-income countries
AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the last 11 months.
Approximately two-thirds of these have gone to low- and lower-middle-income countries, including more than 175 million doses delivered to 130 countries through the COVAX Facility.
This milestone comes just over 18 months after AstraZeneca and Oxford University formed their landmark partnership for the global development and distribution of a not-for-profit COVID-19 vaccine for the world, and less than 12 months after its first emergency authorisation in the UK.1
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Our vaccine has played a key role in tackling the biggest public health emergency of our lifetime: an estimated million lives saved, 50 million infections prevented, two billion doses delivered. The numbers are remarkable, and I’d like to thank everyone who put their lives to one side to help in this incredible endeavour. While much of the world still has to be vaccinated, and there is still much more to do, today is a proud day and testament to what can be achieved when we all work together.”
Professor Sir Andrew J Pollard, Director of Oxford Vaccine Group, said: “This is a proud moment and tribute to the efforts of researchers who developed and tested the vaccine, manufacturing staff who continue to work tirelessly to make it, logistics teams who ship it to clinics in every corner of the earth, armies of vaccinators who get it in our arms, and the public who have been with us since the first clinical trial dose on 23rd April 2020.”
To date, COVID-19 Vaccine AstraZeneca (ChAdOx1-S [Recombinant]) is estimated to have helped prevent 50 million COVID-19 cases, five million hospitalisations, and helped save more than one million lives.2 From the body of evidence in clinical trials and real-world data, the vaccine has been shown to have an acceptable safety profile.3,4,5,6,7
AstraZeneca continues to engage with governments, multilateral organisations and collaborators to ensure broad and equitable access to the vaccine.
COVID-19 Vaccine AstraZeneca
COVID-19 Vaccine AstraZeneca (ChAdOx1-S [Recombinant]) was co-invented by the University of Oxford and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.
The vaccine has been granted a conditional marketing authorisation or emergency use in more than 90 countries. It also has Emergency Use Listing from the World Health Organization, which accelerates the pathway to access in up to 142 countries through the COVAX Facility.
COVID-19 Vaccine AstraZeneca is known as Vaxzevria in Europe. Under a sub-license agreement with AstraZeneca, the vaccine is manufactured and supplied by the Serum Institute of India under the name COVISHIELD.
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
1. AstraZeneca news release: AstraZeneca’s COVID-19 vaccine authorised for emergency supply in the UK https://www.astrazeneca.com/media-centre/press-releases/2020/astrazenecas-covid-19-vaccine-authorised-in-uk.html [Last accessed: November 2021]
2. Data estimates based on a health-economics model with transmission defined as 200 infections per 100,000 people per day. AZD1222 lives and hospitalisations prevented data on file. Data on File Number: REF-131228, 10 November, 2021. AstraZeneca UK Ltd.
3. COVID-19 Vaccine AstraZeneca (ChAdOx1-S [Recombinant]) Summary of Product Characteristics.
4. EMEA report, 11 May 2021: COVID-19 vaccine safety update – Vaxzevria : https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-11-may-2021_en.pdf [Accessed: 24 May 2021]
5. Burn, E et al, Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2: a population-based cohort analysis. Available at: https://www.medrxiv.org/content/10.1101/2021.07.29.21261348v1 [Accessed August 2021]
6. Burn, E et al, Thromboembolic Events and Thrombosis With Thrombocytopenia After COVID-19 Infection and Vaccination in Catalonia, Spain. Available at SSRN: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3886421 [Accessed July 2021]
7. United Nations. Guidelines: Diagnosis and Management of Thrombosis with Thrombocytopenia Syndrome (TTS) following Adenovirus Vectored COVID-19 Vaccinations. Available at https://www.un.org/sites/un2.un.org/files/coronavirus_vipitguidance.pdf. Accessed August 2021.